Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Trial Profile

CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs CAR T cell therapy Hebei Senlang Biotechnology (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Leukaemia; Lymphoma; Myeloma; Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Hebei Senlang Biotechnology
  • Most Recent Events

    • 04 Dec 2018 Results (n=15) assessing the feasibility and safety of CD19 and CD22 Chimeric Antigen Receptors-Modified T Cell Cocktail for Therapy of B Cell Acute Lymphoblastic Leukemia, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 31 Aug 2018 Biomarkers information updated
    • 25 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top